-
4 weeks ago | 
ajmc.com | Rose McNulty |Charles C. Wykoff
With the recent FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), patients with macular telangiectasia type 2 (MacTel) now have an approved treatment option for the progressive retinal condition characterized by irreversible vision loss. In an interview with The American Journal of Managed Care®, clinical investigator Charles C.
-
4 weeks ago | 
ajmc.com | Rose McNulty |Charles C. Wykoff
Revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) recently became the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel), a progressive retinal condition that can cause irreversible vision loss. The newly approved therapy fills a significant unmet need for patients with MacTel and employs a novel method of administration with potential in a broader range of retinal conditions, clinical investigator Charles C.
-
1 month ago | 
ajmc.com | Rose McNulty |Charles C. Wykoff
Following its recent FDA approval, revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) is the first and only therapy indicated for the treatment of macular telangiectasia type 2 (MacTel), a neurodegenerative disease of the retina that causes progressive, irreversible vision loss.1 The allogeneic encapsulated cell-based gene therapy employs a novel strategy for administration that facilitates continual benefits for a patient population that previously had no options.
-
Aug 31, 2024 | 
nature.com | Charles C. Wykoff
Retinal neovascular diseases, such as neovascular age-related macular degeneration (nAMD), diabetic retinopathy (DR), diabetic macular oedema (DMO), and retinal vein occlusion (RVO), are major causes of visual impairment worldwide [1,2,3]. Vascular endothelial growth factor (VEGF) is considered critical in the pathophysiology of these conditions and randomized trials have established the efficacy and safety of agents with an anti-VEGF mechanism of action [4].
-
May 10, 2024 | 
healio.com | Charles C. Wykoff |Anthony DeFino |Christine Klimanskis
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Charles C. Wykoff, MD, PhD, provides anoverview of the Bionic Eye System for late-stage retinitis pigmentosa.
-
Apr 29, 2024 | 
retinalphysician.com | Charles C. Wykoff |Michael Singer
This article was originally published in a sponsored newsletter. This month, I have the pleasure of interviewing my friend, Dr. Charles Wykoff, who is director of research at Retina Consultants of Houston. Dr. Wykoff, recently at the Macula Society meeting, you presented data on a new type of intravitreal injection that could help retinal disease. Can you explain the drug and the setup of the clinical trial? This is one of the most interesting early-phase data sets I have ever seen.
-
Dec 23, 2023 | 
retina-specialist.com | Charles C. Wykoff
Retina specialists are distinctively efficient. We’re used to managing dozens of patients while synthesizing tremendous amounts of data to inform decision-making. Image interpretation is a core strength and a key value we bring to our patients. Most of our optical coherence tomography interpretation is qualitative. Is there fluid? Is there more fluid? Or less? Is the pigment epithelium detachment enlarging? Is the atrophy expanding? This approach appears to be on the edge of a sea-change.
-
Dec 12, 2023 | 
modernretina.com | Charles C. Wykoff
This is a video synopsis of a discussion involving Charles C. Wykoff, MD, PhD, where he presents key findings from a study on the long-term utilization of pegcetacoplan (complement C3 inhibitor) in patients with geographic atrophy (GA). The study, named GALE, extends beyond the preceding DERBY and OAKS trials, focusing on the microperimetry data.
-
Dec 12, 2023 | 
modernretina.com | Charles C. Wykoff
This is a video synopsis of a discussion involving Charles C. Wykoff, MD, PhD, where he provides insights into the GALE study, presenting one-year data on the long-term utilization of pegcetacoplan (complement C3 inhibitor) in patients with geographic atrophy (GA). Dr. Wykoff, a retina specialist in Houston, Texas, notes the study's presentation at the American Academy of Ophthalmology in 2023.
-
Nov 30, 2023 | 
evolvemeded.com | Charles C. Wykoff |Margaret A. Chang |Roger A. Goldberg
Upon completion of this activity, the participant should be able to: Review the prevalence of, and risk factors for, age-related macular degeneration (AMD) and geographic atrophy (GA) Clarify how AMD and GA adversely affect patients’ health and lifestyle, as well as the health care system Examine the complement system’s role in GA and outline which steps in the complement cascade may be effective therapeutic targets Compare the strengths and drawbacks of various imaging platforms and...
